dr. nick benton

OPINION -- February 2, 2012 -- The Supreme Court is going to rule on the case of whether it is constitutional for biotech companies to be able to patent gene sequences. This will be a landmark patent case, since currently about 20 percent of the human genome is patented for various diseases. If the lower court is overturned, it means that a lot of companies that have spent a lot of money making sure they have exclusive rights to commercialization of treatments and testing for specific disease genes, could stand to lose big.